1. De-Novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19
- Author
-
Sidrah Abid, Elio Junior Feghali, Dominick Santoriello, Swati Mehta, and Maha Zafar
- Subjects
Messenger RNA ,Coronavirus disease 2019 (COVID-19) ,business.industry ,General Engineering ,urologic and male genital diseases ,mrna-1273 vaccine ,medicine.disease ,Rheumatology ,acute kidney injury ,Nephrology ,Immunology ,Pathology ,Medicine ,cardiovascular diseases ,pr3-anca ,business ,Vasculitis ,glomerulonephritis ,coronavirus disease (covid-19) ,Anti-neutrophil cytoplasmic antibody - Abstract
Antineutrophil cytoplasmic antibody (ANCA) is a systemic autoimmune disorder characterized by antibodies directed against small- and moderate-sized vessels. While there are few reported cases of autoimmune illnesses associated with influenza vaccination, two cases of de-novo anti-proteinase (PR3) ANCA-associated pauci immune glomerulonephritis are reported after the mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine. Here, we report the third case of ANCA-associated glomerulonephritis after the mRNA-1273 COVID-19 vaccine. Our patient presented with acute kidney injury and sub-nephrotic proteinuria four days after receiving the second dose of the COVID vaccine. He was found to have elevated c-ANCA and anti-PR3 antibodies. Renal biopsy confirmed focal necrotizing and diffuse crescentic glomerulonephritis. He was diagnosed with pauci immune glomerulonephritis. The patient achieved remission 10 weeks after the diagnosis with successful treatment.
- Published
- 2021
- Full Text
- View/download PDF